314 related articles for article (PubMed ID: 17536013)
1. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
Yang Y; MacLeod V; Dai Y; Khotskaya-Sample Y; Shriver Z; Venkataraman G; Sasisekharan R; Naggi A; Torri G; Casu B; Vlodavsky I; Suva LJ; Epstein J; Yaccoby S; Shaughnessy JD; Barlogie B; Sanderson RD
Blood; 2007 Sep; 110(6):2041-8. PubMed ID: 17536013
[TBL] [Abstract][Full Text] [Related]
2. Shed syndecan-1 translocates to the nucleus of cells delivering growth factors and inhibiting histone acetylation: a novel mechanism of tumor-host cross-talk.
Stewart MD; Ramani VC; Sanderson RD
J Biol Chem; 2015 Jan; 290(2):941-9. PubMed ID: 25404732
[TBL] [Abstract][Full Text] [Related]
3. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis.
Yang Y; Macleod V; Miao HQ; Theus A; Zhan F; Shaughnessy JD; Sawyer J; Li JP; Zcharia E; Vlodavsky I; Sanderson RD
J Biol Chem; 2007 May; 282(18):13326-33. PubMed ID: 17347152
[TBL] [Abstract][Full Text] [Related]
4. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.
Ritchie JP; Ramani VC; Ren Y; Naggi A; Torri G; Casu B; Penco S; Pisano C; Carminati P; Tortoreto M; Zunino F; Vlodavsky I; Sanderson RD; Yang Y
Clin Cancer Res; 2011 Mar; 17(6):1382-93. PubMed ID: 21257720
[TBL] [Abstract][Full Text] [Related]
5. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation.
Dhodapkar MV; Abe E; Theus A; Lacy M; Langford JK; Barlogie B; Sanderson RD
Blood; 1998 Apr; 91(8):2679-88. PubMed ID: 9531576
[TBL] [Abstract][Full Text] [Related]
6. High heparanase activity in multiple myeloma is associated with elevated microvessel density.
Kelly T; Miao HQ; Yang Y; Navarro E; Kussie P; Huang Y; MacLeod V; Casciano J; Joseph L; Zhan F; Zangari M; Barlogie B; Shaughnessy J; Sanderson RD
Cancer Res; 2003 Dec; 63(24):8749-56. PubMed ID: 14695190
[TBL] [Abstract][Full Text] [Related]
7. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.
Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D
J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925
[TBL] [Abstract][Full Text] [Related]
8. Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma.
Reijmers RM; Groen RW; Rozemuller H; Kuil A; de Haan-Kramer A; Csikós T; Martens AC; Spaargaren M; Pals ST
Blood; 2010 Jan; 115(3):601-4. PubMed ID: 19965677
[TBL] [Abstract][Full Text] [Related]
9. Soluble syndecan-1 promotes growth of myeloma tumors in vivo.
Yang Y; Yaccoby S; Liu W; Langford JK; Pumphrey CY; Theus A; Epstein J; Sanderson RD
Blood; 2002 Jul; 100(2):610-7. PubMed ID: 12091355
[TBL] [Abstract][Full Text] [Related]
10. Heparan sulfate proteoglycans and heparanase--partners in osteolytic tumor growth and metastasis.
Sanderson RD; Yang Y; Suva LJ; Kelly T
Matrix Biol; 2004 Oct; 23(6):341-52. PubMed ID: 15533755
[TBL] [Abstract][Full Text] [Related]
11. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis.
Purushothaman A; Uyama T; Kobayashi F; Yamada S; Sugahara K; Rapraeger AC; Sanderson RD
Blood; 2010 Mar; 115(12):2449-57. PubMed ID: 20097882
[TBL] [Abstract][Full Text] [Related]
12. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.
Ramani VC; Purushothaman A; Stewart MD; Thompson CA; Vlodavsky I; Au JL; Sanderson RD
FEBS J; 2013 May; 280(10):2294-306. PubMed ID: 23374281
[TBL] [Abstract][Full Text] [Related]
13. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.
Mahtouk K; Hose D; Raynaud P; Hundemer M; Jourdan M; Jourdan E; Pantesco V; Baudard M; De Vos J; Larroque M; Moehler T; Rossi JF; Rème T; Goldschmidt H; Klein B
Blood; 2007 Jun; 109(11):4914-23. PubMed ID: 17339423
[TBL] [Abstract][Full Text] [Related]
14. Syndecan-1: a dynamic regulator of the myeloma microenvironment.
Sanderson RD; Yang Y
Clin Exp Metastasis; 2008; 25(2):149-59. PubMed ID: 18027090
[TBL] [Abstract][Full Text] [Related]
15. Heparanase regulates levels of syndecan-1 in the nucleus.
Chen L; Sanderson RD
PLoS One; 2009; 4(3):e4947. PubMed ID: 19305494
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse.
Ramani VC; Sanderson RD
Matrix Biol; 2014 Apr; 35():215-22. PubMed ID: 24145151
[TBL] [Abstract][Full Text] [Related]
17. Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis.
Ren Z; Spaargaren M; Pals ST
Blood; 2021 Apr; 137(13):1713-1718. PubMed ID: 33512430
[TBL] [Abstract][Full Text] [Related]
18. Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo.
Khotskaya YB; Dai Y; Ritchie JP; MacLeod V; Yang Y; Zinn K; Sanderson RD
J Biol Chem; 2009 Sep; 284(38):26085-95. PubMed ID: 19596856
[TBL] [Abstract][Full Text] [Related]
19. Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype.
Purushothaman A; Hurst DR; Pisano C; Mizumoto S; Sugahara K; Sanderson RD
J Biol Chem; 2011 Sep; 286(35):30377-30383. PubMed ID: 21757697
[TBL] [Abstract][Full Text] [Related]
20. Heparanase-1-induced shedding of heparan sulfate from syndecan-1 in hepatocarcinoma cell facilitates lymphatic endothelial cell proliferation via VEGF-C/ERK pathway.
Yu S; Lv H; Zhang H; Jiang Y; Hong Y; Xia R; Zhang Q; Ju W; Jiang L; Ou G; Zhang J; Wang S; Zhang J
Biochem Biophys Res Commun; 2017 Apr; 485(2):432-439. PubMed ID: 28209511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]